iTeos Therapeutics’ (ITOS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research report report published on Monday, Benzinga reports. HC Wainwright currently has a $46.00 price target on the stock.

Several other research firms have also recently commented on ITOS. Wells Fargo & Company began coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They set an overweight rating and a $31.00 target price on the stock. Wedbush reissued an outperform rating and set a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. dropped their target price on shares of iTeos Therapeutics from $27.00 to $24.00 and set an overweight rating on the stock in a research report on Monday, August 12th.

iTeos Therapeutics Price Performance

Shares of ITOS opened at $11.59 on Monday. The stock has a 50-day moving average of $16.12 and a 200-day moving average of $14.63. The company has a market cap of $418.67 million, a PE ratio of -3.07 and a beta of 1.39. iTeos Therapeutics has a one year low of $8.20 and a one year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.86. The business had revenue of $35.00 million during the quarter, compared to the consensus estimate of $4.20 million. Analysts expect that iTeos Therapeutics will post -4.21 EPS for the current fiscal year.

Institutional Investors Weigh In On iTeos Therapeutics

Hedge funds have recently modified their holdings of the stock. Quest Partners LLC bought a new stake in shares of iTeos Therapeutics in the 4th quarter worth approximately $90,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of iTeos Therapeutics by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,877 shares of the company’s stock worth $94,000 after purchasing an additional 2,737 shares during the period. Aristides Capital LLC bought a new stake in shares of iTeos Therapeutics in the 4th quarter worth approximately $157,000. The Manufacturers Life Insurance Company grew its stake in iTeos Therapeutics by 6.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after buying an additional 690 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in iTeos Therapeutics by 35.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock valued at $178,000 after buying an additional 3,172 shares in the last quarter. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.